Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients).

[2] It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.

[2] Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.

[3] Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.

[5][6] This drug article relating to the nervous system is a stub.